Navigation Links
Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia

BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc. today is presenting data from an open-label extension of its Phase IIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD) at the Alzheimer's Association's International Conference on Prevention of Dementia in Washington, D.C. Consistent with the findings of earlier clinical and preclinical studies, AC-1202 was shown to be safe and to significantly improve the memory and cognition of subjects of a particular pharmacogenomic profile.

The randomized, double-blinded, placebo-controlled Phase IIb trial evaluated 152 subjects that had previously been diagnosed with mild to moderate AD at 25 centers across the United States. AC-1202 was administered once daily, and most patients continued to take their other AD drugs such as acetylcholinesterase inhibitors. Following three months of treatment and a two-week washout, eligible subjects were given the opportunity to receive AC- 1202 in a six-month open-label extension study. The main clinical outcome for efficacy was improvement in the AD Assessment Scale-Cognitive (ADAS-Cog) score, which measures memory and other aspects of cognitive performance.

In the double-blind phase of the clinical study the ADAS-Cog scores of the AC-1202-treated ApoE4(-) population improved 3.5 points in twelve weeks (p=0.01) compared to the placebo group, and statistically significant improvement was seen in just 45 days. ApoE4(-) subjects who also exhibited a genetic variation that affects glucose regulation showed a 5-point improvement in ADAS-Cog scores compared to placebo, providing further insight into the disease.

As in the double-blind phase of the study, the most profound effect was seen in subjects not expressing the ApoE4 genotype, a genetic risk factor for AD. ApoE4(-) subjects represent the other half of Alzheimer's patients. ApoE4(-) subjects who started taking AC-1202 on the open-label e
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accera, Inc. Announces Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/28/2014)... und LONDON , July ... , Ziel der Zusammenarbeit sind Entwicklung und Kommerzialisierung ... Plasmaproben zur Steuerung von Therapien mit IRESSA bei ... Neuer Bluttest basiert auf QIAGENs von der ... Rotor-Gene Q, einer Automationsplattform der QIAsymphony-Produktfamilie, laufen  ...
(Date:7/28/2014)... , Germany and ... , Collaboration aims to create and ... to guide the use of IRESSA  for non-small cell ... build on QIAGEN,s FDA-approved  therascreen   EGFR test and is ... of automated instruments  Project enabled by AstraZeneca ...
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma ... it will report its second quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... Receiving the herpes zoster vaccine was associated with a ... Kaiser Permanente study of 300,000 people that appears in the ... Association . This retrospective study observed the outcomes ... large, diverse population of men and women ages 60 years ...
... 11, 2011 Celleration, Inc., a privately held medical ... products, today announced the closing of an $8 million ... Company,s existing institutional investors participated in this round in ... a new investor. "The addition of ...
Cached Medicine Technology:Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 2Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 3Shingles Vaccine Associated With 55 Percent Reduced Risk of Disease 4
(Date:7/28/2014)... (PRWEB) July 28, 2014 To commemorate ... Editorial Board of Living with a Disability magazine ... disabling digestive disorders that include hepatitis, gastrointestinal hemorrhage, inflammatory ... , The important new article highlights that, in the ... afflicted with hepatitis and other disabling conditions related to ...
(Date:7/28/2014)... July 28, 2014 According to the Heartburn ... a comprehensive guide that will help people get rid of ... all the necessary information about heartburn and acid reflux. In ... about heartburn , and risk factors for reflux disease. ... help people get rid of symptoms of reflux disease naturally ...
(Date:7/28/2014)... According to the Drama Method Pdf review ... that helps women easily get the attention of the men ... in its review that this book can teach ladies how ... The book also instructs them how to conquer a man, ... Drama Method review that this book is divided into 30 ...
(Date:7/28/2014)... 2014 Building a sense of neighborhood ... Where personal outdoor space is not possible, building ... fun and exercise outside is important. That’s why ... quality commercial playground equipment from APCPLAY. , Old Buckingham ... Virginia. It is an historic tourist location of one ...
(Date:7/28/2014)... Mitul R. Patel, DDS and concerned leading Dentists ... Experts Benefit Dinner May 30, in St. Petersburg, FL. ... raise funds for the Improving Youth Literacy Campaign in ... Programs across America. The funds raised are providing hundreds ... books to directly tackle illiteracy and help to break ...
Breaking Medicine News(10 mins):Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 2Health News:The Drama Method Pdf Review Exposes Aaron Fox's Relationship Guide – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 2Health News:Mitul R. Patel, DDS Successfully Attacks a Major Source of Economic Destruction in the Battle Against Illiteracy and Poverty 3
... depression, study suggests , , WEDNESDAY, Aug. 29 (HealthDay News) -- ... be as simple as seeing which arm she uses to ... mothers who cradle their baby on their right side may ... mothers feel some levels of stress during the first weeks ...
... a 58-year-old business owner from Waxahachie, Texas, was fortunate. ... but a side effect of his successful surgery was ... cancer, I started experiencing incontinence, said Mr. Yarborough, who ... better than most, the condition, simply put, drove me ...
... anesthesia, faster recovery, less cost, study finds , , TUESDAY, Aug. ... may ease the pain of surgery -- both during and ... who received hypnosis before breast cancer surgery needed less anesthesia ... in the operating room and had reduced costs. , ...
... and therapies, researchers say , , TUESDAY, Aug. 28 (HealthDay ... of multiple sclerosis patients may help predict the severity ... reporting. , "This is a new way to ... of the patient,s lesions," said lead researcher Dr. Rohit ...
... ear, nose and throat specialists at Thomas Jefferson University ... apnea syndrome. , In the procedure, known as Genial ... lower jaw which attaches to the tongue is moved ... of the airway, increasing the airway space. It is ...
... Genes connected with higher functions are changed by continued ... -- Alcoholics with cirrhosis (scarring and dysfunction) of the ... according to new research. , Researchers examined gene expression ... alcoholics with cirrhosis and 14 alcoholics without cirrhosis. , ...
Cached Medicine News:Health News:Stressed-Out Moms Carry Babies on the Right 2Health News:New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence 2Health News:Hypnosis Eases Pain of Breast Cancer Surgery 2Health News:Hypnosis Eases Pain of Breast Cancer Surgery 3Health News:Brain Lesions Predict MS Progression 2Health News:Brain Lesions Predict MS Progression 3Health News:Jefferson specialists studying innovative surgery for effectively treating sleep apnea 2Health News:Alcoholics With Cirrhosis Have More Brain Damage 2
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Anatomical implants for the entire hand, in five sizes...
... a brief magnetic pulse to stimulate deep ... in Magnetic Nerve Stimulators. Based upon equipment ... in 1985. A powerful monophasic stimulator for ... best stimulator for Central Motor Conduction Studies, ...
Medicine Products: